NCT07354932

A Study of SHR-2173 in Participants With Primary IgA Nephropathy

A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-2173 Injection in Patients With Primary IgA Nephropathy

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 84 (estimated)
• Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is a randomized, double-blind, placebo-controlled Phase II clinical trial to evaluate the efficacy and safety of SHR-2173 in patients with Primary IgA Nephropathy(IgAN). The study consists of a screening period, a run-in period, a 48-week double-blind treatment period, and a 12-week follow-up period. Approximately 84 IgAN patients will be included.

Conditions

• Primary IgA Nephropathy

Interventions

Type	Name	Description
DRUG	SHR-2173 injection	SHR-2173 injection；High dose
DRUG	SHR-2173 injection	SHR-2173 injection；Medium dose
DRUG	SHR-2173 injection	SHR-2173 injection；Low dose
DRUG	Placebo	Placebo

Timeline

• Start date: 2026-02-01
• Primary completion: 2027-04-01
• Completion: 2027-12-01
• First posted: 2026-01-21
• Last updated: 2026-01-21

Locations

2 sites across 1 country: China